ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
The EU recommendation for odronextamab comes after a US rejection in March.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
The company defends its cancer strategy, and says it's not a me-too developer.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.